How to best use high-sensitivity cardiac troponin in patients with suspected myocardial infarction
Standard
How to best use high-sensitivity cardiac troponin in patients with suspected myocardial infarction. / Twerenbold, Raphael; Boeddinghaus, Jasper; Nestelberger, Thomas; Wildi, Karin; Rubini Gimenez, Maria; Badertscher, Patrick; Mueller, Christian.
In: CLIN BIOCHEM, Vol. 53, 03.2018, p. 143-155.Research output: SCORING: Contribution to journal › SCORING: Review article › Research
Harvard
APA
Vancouver
Bibtex
}
RIS
TY - JOUR
T1 - How to best use high-sensitivity cardiac troponin in patients with suspected myocardial infarction
AU - Twerenbold, Raphael
AU - Boeddinghaus, Jasper
AU - Nestelberger, Thomas
AU - Wildi, Karin
AU - Rubini Gimenez, Maria
AU - Badertscher, Patrick
AU - Mueller, Christian
N1 - Copyright © 2017 The Canadian Society of Clinical Chemists. Published by Elsevier Inc. All rights reserved.
PY - 2018/3
Y1 - 2018/3
N2 - High-sensitivity cardiac troponin (hs-cTn) assays have been used clinically by thousands of physicians in many countries throughout the world since their clinical introduction seven years ago. In the early diagnosis of myocardial infarction (MI), beyond doubt the most important indication of hs-cTn assays, these simple, inexpensive and highly reproducible tools complement detailed clinical assessment including chest pain characteristics and the electrocardiogram. Hs-cTn assays for the first time allowed the precise quantification of cardiomyocyte injury around the 99th percentile and thereby substantially increased the accuracy of MI detection from blood obtained at presentation to the emergency department (ED). Higher accuracy at ED presentation enabled the development and extensive validation of early hs-cTn-based diagnostic algorithms, which substantially reduced the time required for the safe rule-out or rule-in of MI. This review summarizes key principles underlying the safe and effective use of hs-cTn in the ED in patients with suspected MI.
AB - High-sensitivity cardiac troponin (hs-cTn) assays have been used clinically by thousands of physicians in many countries throughout the world since their clinical introduction seven years ago. In the early diagnosis of myocardial infarction (MI), beyond doubt the most important indication of hs-cTn assays, these simple, inexpensive and highly reproducible tools complement detailed clinical assessment including chest pain characteristics and the electrocardiogram. Hs-cTn assays for the first time allowed the precise quantification of cardiomyocyte injury around the 99th percentile and thereby substantially increased the accuracy of MI detection from blood obtained at presentation to the emergency department (ED). Higher accuracy at ED presentation enabled the development and extensive validation of early hs-cTn-based diagnostic algorithms, which substantially reduced the time required for the safe rule-out or rule-in of MI. This review summarizes key principles underlying the safe and effective use of hs-cTn in the ED in patients with suspected MI.
KW - Algorithms
KW - Electrocardiography
KW - Humans
KW - Myocardial Infarction/diagnosis
KW - Myocytes, Cardiac/metabolism
KW - Troponin C/blood
U2 - 10.1016/j.clinbiochem.2017.12.006
DO - 10.1016/j.clinbiochem.2017.12.006
M3 - SCORING: Review article
C2 - 29253510
VL - 53
SP - 143
EP - 155
JO - CLIN BIOCHEM
JF - CLIN BIOCHEM
SN - 0009-9120
ER -
